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Abstract
Background Postoperative pancreatic fistula (POPF) is a severe complication after pancreatic resections. The aim was to
assess if application of TachoSil® patch could reduce incidence of postoperative fistulas after laparoscopic distal pancreatic
resections.
Methods This is a retrospective study of prospectively collected data after enucleations and distal pancreatic resections.
Patients were divided in two groups: with or without application of TachoSil® patch. Demographic and surgical data were
analyzed.
Results One hundred twenty-one patients with distal pancreatic resections without additional resections were identified
among 230 patients operated by laparoscopic approach at our institution since 1998. They were divided into two groups. In
group 1 (n=48), TachoSil® patch was not applied while in group 2 (n=73), the pancreatic stump was covered with
TachoSil®. Postoperative fistulas were registered in 8% (4/48) and 12% (9/73) in groups 1 and 2, respectively. The median
duration of postoperative hospital stay in group 1 was 5.5 (2–35) days compared with 5 (2–16) days in group 2. No
significant difference in surgical outcomes was found.
Conclusions The application of the TachoSil® patch did not affect either occurrence of POPF or duration of postoperative
hospital stay. Routine use of TachoSil® patch to prevent pancreatic fistulas does not provide clinically significant benefit.
Keywords Postoperative complication.Pancreatic fistula.
TachoSil.Pancreas resection
Introduction
The laparoscopic approach for distal pancreatic resections
has gained increased acceptance for several indications
during the past decade and an increasing number of patients
is operated by this method both for nonmalignant as well as
for malignant diseases. There is increasing documentation
that both endocrine tumors, cystic lesions, metastatic
lesions, and adenocarcinomas can be safely operated by
the laparoscopic approach
1–3 and the implementation of
minimally invasive techniques has led to reduced morbid-
ity.
4,5 Despite this, perioperative bleeding and pancreatic
leakage still remain a challenge for the surgeons. General
morbidity rate and perioperative hemorrhage is generally
lower for laparoscopic procedures
6,b u tt h e r ei sn o
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to reduced POPF rate after distal pancreas resections.
V arious centers have published different rates of POPF
varying from 0% to 32% as defined by the International
study group on pancreatic fistulas (ISGPF).
7 In our
institution, the overall fistula rate after laparoscopic
resections of the pancreas has been 10%.
2
The continuous search for the new and more effective
remedies and techniques to prevent POPF remains is
important. In January 2005, we introduced the surgical patch
TachoSil® (Nycomed, Pharmaceutical Co. Ltd, Denmark) to
cover the resection margin of the pancreas after laparoscopic
resections. It was announced as a fast and reliable remedy for
haemostasis and sealing of soft tissues. These argued
characteristics corresponded to our needs in order to prevent
postoperative complications.This study evaluated TachoSilas
a prevention remedy for postoperative pancreatic fistula
(POPFs) in pancreatic surgery.
Patients and Methods
Patients
A total of 230 patients underwent laparoscopic pancreas
resections in our institution from March 1997 to December
2010. After exclusion of local tumor resections (n=36),
procedures with additional resections of adjacent organs
(n=29), procedures where other types of protection of
surgical margin were used (n=14), converted procedures
or accomplished as hand assisted (n=5), and explorative
and other types of procedures (n=25) a total of 121
patients undergoing distal pancreatic resection (DPR) with
or without splenectomy, were left for analysis. All
procedures were performed by the same group of
surgeons. From January 2005 majority of the procedures
have been completed with covering of surgical margin and
part of pancreatic remnant by TachoSil patch for to prevent
postoperative pancreatic fistulas and potential postopera-
tive bleeding. To that time not all effects of this remedy
were clear and good documented, especially about its
effectiveness in pancreatic surgery.
Indications to surgical procedures were endocrine
tumors, cystic lesions, adenocarcinomas, and others as
described in our previous publication.
The patients were retrospectively divided in two groups
according to the final management of the surgical margin.
In the first group (group 1, consisting of 48 patients (32
women and 16 men) with a median age of 62 (30–81) years
and median ASA score of 2 (1–3)), the pancreas was
divided by a linear stapler and left without additional
covering. In the second group (group 2, consisting of 73
patients (49 women and 24 men) with a median age of 60
(16–82) years and median ASA score of 2 (1–3)), the staple
line of the resection margin was covered with a TachoSil®
patch. As our method for pancreas division has been
described in detail earlier,
2,8 this study focused only on
the final part of the procedure.
Data were analyzed retrospectively. Patient’s character-
istics are presented in Table 1.
Outcome Parameters
According to the ISGPF definition, pancreatic fistula was
defined as a drainage fluid beyond the third postoperative
day with at least threefold elevation of normal serum
amylase. The grading system (grades A, B, and C) of
severity of pancreatic fistula was applied (Table 2).
9
Postoperative complications were registered in accordance
with a last revision of the accordion classification, from mild
complications (grade 1) to death of the patient—(grade 6) as
described in Table 3.
10
Statistical Analysis
Statistical analysis was conducted using SPSS 16, 0. Data
were presented as median (range). For comparison of
frequencies, the Chi-square test was performed. For
comparison of the continuous variables, Mann–Whitney U
test was used.
Results
Out of 230 patients, 121 were included in this study of
which 91 were DPR with splenectomy and 30 were DPR
performed as spleen-preserving procedures. Details regard-
ing the indications for surgery are summarized in Table 4.
All procedures were completed laparoscopically. Data
regarding the surgical details are described in Table 5:
In group 1, 38 DPR with splenectomy and ten spleen-
preserving resections were performed without using Tacho-
Sil. The median operative time for these procedures was
202 (29–350) minutes and the median intraoperative
bleeding was 50 (0–1,500) ml. There were three grade 1,
two grade 2, four grade 3, and two grade 4 events. Four
Table 1 Patient characteristics
Group 1 Group 2
Patients 48 73
Gender 32 women 49 women
16 men 24 men
Median age (years) 62 (30–81) 60 (16–82)
Median ASA score 2 (1–3) 2 (1–3)
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grade B. The overall morbidity in the group was 30%. The
median duration of postoperative hospital stay for group 1
was 5 (2–16) days.
In group 2, we included only those procedures where the
pancreatic remnant was covered with TachoSil®. In this
group, 53 procedures were DPR with splenectomy and 20
spleen-preserving DPR. The median operative time was
158 (88–608) min, and the median intraoperative bleeding
was 50 (5–3,000) ml. The postoperative morbidity included
four grade 1 event, three grade 2, one grade 3 event, and
three grade 4 events. Postoperative pancreatic leakage was
registered in ten patients of which one grade A, six grade B,
and three grade C fistulas. The overall morbidity rate in
group 2 was 30%, and the median duration of postoperative
hospital stay was 5.5 (2–35) days.
No postoperative mortality was recorded in any of the
groups. Detailed description over all postoperative compli-
cations is shown in Table 6. We did not find statistical
difference in postoperative data between these two groups.
Discussion
Laparoscopic DPR have steadily gained acceptance as a
method for surgical removal of both benign and malignant
lesions in the tail and body of the pancreas.
The technique not only shows better cosmetic results but
is also associated with reduced bleeding and overall
morbidity rate compared with traditional open surgery.
11 It
is unclear if the method influences the rate of postoperative
pancreatic leakage since no randomized studies has been
conducted while comparing the techniques. There are,
however, studies in which a trend has been reported about
nonsignificant reduced rate of POPF after minimally
invasive procedures.
6
Pancreatic leakage is one of the most commonly
encountered severe complications following pancreatic
resections and leak rates up to 46% has been described.
12
Several different techniques have been attempted in order to
prevent fistulas and some authors mean that management of
Table 3 Revised accordion classification
Grade Revised accordion classification
Mild
1 Requires only minor invasive procedures that can be done
at the bedside, such as insertion of intravenous lines,
urinary catheters, and nasogastric tubes and drainage of
wound infections. Physiotherapy and anti-emetics,
antipyretics, analgesics, diuretics, electrolytes, and
physiotherapy are permitted
Moderate
2 Requires pharmacologic treatment with drugs other than
such allowed for minor complications, e.g., antibiotics.
Blood transfusions and total parenteral nutrition are also
included
Severe
3 No general anesthesia: requires management by an
endoscopic, interventional procedure or reoperation
without general anesthesia
4 General anesthesia or single-organ failure
5 General anesthesia and single-organ failure or multisystem
organ failure (>2 organ systems)
Death
6 Postoperative death
Grade A B C
Clinical conditions Well Often well Ill appearing/bad
Specific treatment
a No Yes/no Yes
US/CT (if obtained) Negative Negative/positive Positive
Persistent drainage (after 3 weeks)
b No Usually yes Yes
Reoperation No No Yes
Death related to POPF No No Possibly yes
Signs of infections No Yes Yes
Sepsis No No Yes
Readmission No Yes/no Yes/no






aPartial (peripheral) or total
parenteral nutrition, antibiotics,
enteral nutrition, somatostatin
analog, and/or minimal invasive
drainage
bWith or without a drain in situ
Table 4 Summary of details regarding the indications for surgery
Indication to surgery Group 1 Group 2
Cystic lesions 17 34
PNET
Malign lesions 6 4
Benign lesions 15 14
Exocrine adenocarcinoma 5 9
Metastatic lesions 2 0
Pancreatitis 1 9
Abdominal trauma 0 1
V ascular formation 2 2
Total 48 73
J Gastrointest Surg (2011) 15:1625–1629 1627the resectional margin of pancreatic stump is very important.
To develop a standardized technique which can demonstrate a
significant decrease in overall morbidity including fistula
formation is important.
Better results and safety of the patient is a major concern
of any surgical procedures and laparoscopic pancreas
resection is no exception. One contribution for the
decreased overall morbidity in pancreatic surgery during
the last years is the introduction of new staplers, electro-
surgical instruments, surgical methods, and other technical
and pharmaceutical remedies. TachoSil® is a fixed
combination of a patch sponge coated with a dry layer
of the human coagulation factors fibrinogen and thrombin.
TachoSil® is indicated for supportive treatment in surgery,
for improvement of haemostasis, to promote tissue sealing
and for suture support in vascular surgery where standard
techniques are insufficient.
The haemostatic effect of Tachosil patch in surgical
procedures is well documented in the literature
13 in a wide
variety of organs.
14
Since the TachoSil® patch was also reported to be of value
interms ofsealingsurgical resectionsurfaces; wepostulatedit
to be of value also in pancreas resections in which fistula
formation continued to constitute a problem. Covering of the
stapling line on the cut surface of the pancreas therefore
became a routine part of the procedure since 2005.
It was described as predicting factors for development of
pancreatic fistulas
15, and we tried to look if TachoSil®
Table 5 Data regarding surgical details
Surgical outcomes Group 1
a Group 2
b p value
DPR with splenectomy 38 53
Spleen-preserving resections 10 20
Operative time (min) 202 (29–350) 158 (88–480) 0.810
Bleeding (ml) 50 (0–1,500) 50 (0–3,000) 0.970
Duration of postoperative hospital stay 5 (2–16) 5.5 (2–35) 0.203
PNET pancreatic neuroendocrine tumor
aPancreatic stump was not covered
bResectional pancreatic stump was covered with TachoSil patch
Table 6 Detailed description over all postoperative complications
Postoperative complications Group 1
a Group 2
b p value
Fistula formation 4 (8%) 10 (14%) 0,487
Grade A 0 1
Grade B 4 6
Grade C 0 3
Other morbidity 11 (23%) 11 (15%)
Severity grade
Mild
1 4—2 small hematomas around the resection
area, urine retention, and wound infection
3—urine retention, pleural liquid collection,
and wound infection
Moderate
2 3—postoperative abscess and 2 fibers 2—postoperative bleeding and subcapsular
splenic hematoma
Severe
3 1—intraabdominal abscess 4—Abscess in operation area, subphrenic
hematoma, and 2 wound fractures




Overall morbidity 15(30%) 21 (30%)
aPancreatic stump was not covered
bResectional pancreatic stump was covered with TachoSil patch
1628 J Gastrointest Surg (2011) 15:1625–1629patch could be beneficial in special cases. In the present
series, we found that in the first group (without application
of TachoSil) fistulas were registered only in soft glands
whereas in the second (where TachoSil was applied on the
resectional line) 30% (three out of ten) of all fistulas
developed in the hard glands. To make any conclusions
based on these results is difficult. We did not experience
serious blood loss (≤1,000 ml) in any of these cases.
When we designed this retrospective study we were
aware about its limitations and have tried to diminish their
possibility. To avoid selection bias only distal resections
with or without splenectomy independent of other factors
(age, pathology, etc.) were included to the study. Chances
that some of the patients fall out of control were equal for
both groups. However, due to general low rate of fistulas in
our material, one should be aware about possibility of
statistical type 2 error.
In this study, however we did not observe significant
differences in any of the studied parameters between
patients in whom stapling line was covered by TachoSil
patch after the resection and those without it. Somewhat
surprisingly, grade C fistulas were only observed in patients
in group 2, in which TachoSil® was used. The reason for
this is unclear. One possible explanation could be that
reducing of the natural outflow from the pancreatic remnant
can lead to accumulation of ferments and thereby impair the
normal process of postoperative healing. To make any
conclusion about this, randomized studies are needed.
The haemostatic effect of TachoSil® in various procedures
makes the product of great value in complex laparoscopic
procedures.
Present data do not support the use of the TachoSil®
patch for the prevention of fistulas following distal
pancreatic resections.
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